Stock ARIAD PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Ariad Pharmaceuticals, Inc. Stock

Equities

US04033A1007

Biotechnology & Medical Research

End-of-day quote Nasdaq
Other stock markets
- USD - Intraday chart for Ariad Pharmaceuticals, Inc.
2017 Takeda Pharmaceutical : Japan's Takeda ready for fresh acquisitions after $5.2 billion Ariad deal RE
2014 Dai ichi Life Insurance : U.S. futures flat with Dow, S&P at record levels RE

Latest news about Ariad Pharmaceuticals, Inc.

Takeda Pharmaceutical : Japan's Takeda ready for fresh acquisitions after $5.2 billion Ariad deal RE
Dai ichi Life Insurance : U.S. futures flat with Dow, S&P at record levels RE
Insight: Shorts set to pounce as stocks seen pricey, Fed pulls back RE
Prosensa Holding NV : Investment risks of fast-tracking biotech drugs become apparent RE
Onyx Pharmaceuticals, Inc. : Pfizer, Novartis may join Amgen in bidding for Onyx: sources RE
Actelion Ltd : New Amgen CEO must win investors with payouts, deals RE
More news

Press releases Ariad Pharmaceuticals, Inc.

Ariad Pharmaceuticals : Announces Submission of Marketing Authorization Application for Brigatinib to the European Medicines Agency BU
Ariad Pharmaceuticals : Enters into Definitive Agreement to Be Acquired by Takeda for $5.2 Billion PU
Ariad Pharmaceuticals : Takeda to Acquire ARIAD Pharmaceuticals, Inc. PU
Ariad Pharmaceuticals : Acquisition May Not Be in the Best Interests of ARIA Shareholders PR
Brower Piven Commences An Investigation Into The Proposed Sale Of ARIAD Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information BU
More press releases

News in other languages on Ariad Pharmaceuticals, Inc.

Takeda Pharmaceutical : rachète l'américain Ariad pour 5,2 milliards de dollars
Ariad Pharmaceuticals : Incyte et ARIAD annoncent un accord dans le cadre duquel Incyte rachètera les opérations européennes d'ARIAD et vendra sous licence Iclusig® (ponatinib) en Europe
Ariad Pharmaceuticals : Incyte und ARIAD geben Vereinbarung zur Übernahme des europäischen Geschäfts von ARIAD durch Incyte und die Einlizenzierung von Iclusig® (Ponatinib) in Europa bekannt
Ariad Pharmaceuticals : annonce le début de l’essai randomisé de phase III OPTIC-2L comparant le ponatinib au nilotinib dans le traitement de deuxième ligne de patients atteints de leucémie myéloïde chronique en phase chronique
Ariad Pharmaceuticals : meldet Start der randomisierten Phase-3-Studie OPTIC-2L zum Vergleich von Ponatinib mit Nilotinib als Zweitlinientherapie bei Patienten mit chronischer myeloischer Leukämie in der chronischen Phase
More news

Managers and Directors - Ariad Pharmaceuticals, Inc.

Managers TitleAgeSince
Teresa Bitetti PSD
 President - -
Tetsu Inada BRD
 Director/Board Member - -
Jason E. Baranski SEC
 Corporate Secretary - -
Members of the board TitleAgeSince
Teresa Bitetti PSD
 President - -
Tetsu Inada BRD
 Director/Board Member - -
More insiders

Company Profile

More about the company

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-3.10% 102B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+2.11% 96.07B
ARGENX SE Stock argenx SE
-1.80% 21.66B
BIONTECH SE Stock BioNTech SE
-17.75% 20.77B
GENMAB A/S Stock Genmab A/S
-6.91% 18.53B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-42.00% 16.91B
BEIGENE, LTD. Stock BeiGene, Ltd.
-28.19% 13.79B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+0.18% 13.33B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+19.90% 10.94B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. Stock